In vitro chemosensitivity of human soft tissue sarcoma

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Chemotherapy is crucial for small round cell sarcomas but lacks efficacy in other soft tissue tumors (STS).
• The Histoculture Drug Response Assay (HDRA) is a validated in vitro chemosensitivity test for solid tumors, but its application in STS was previously unreported.

Purpose of the Study:

• To investigate the chemosensitivity variations in different types of soft tissue sarcomas (STS).
• To evaluate the utility of the Histoculture Drug Response Assay (HDRA) for assessing drug sensitivity in STS.

Main Methods:

• Fresh biopsy or surgical samples from 33 soft tissue sarcomas (STS) were tested using the Histoculture Drug Response Assay (HDRA).
• Drug sensitivity was assessed by measuring the inhibitory rates of Doxorubicin (ADM), Trabectedin (THP), Cisplatin (CDDP), Ifosfamide (IFOS), and Etoposide (VP-16).

Main Results:

• Doxorubicin (ADM) and Trabectedin (THP) showed significantly higher inhibitory rates compared to Cisplatin (CDDP), Ifosfamide (IFOS), or Etoposide (VP-16) across all tested STS.
• Spindle cell sarcomas exhibited sensitivity to Trabectedin (THP), while pleomorphic cell sarcomas showed low sensitivity except to Doxorubicin (ADM) and Trabectedin (THP).
• Small round cell sarcomas demonstrated relative sensitivity to all tested chemotherapeutic agents.

Conclusions:

• The Histoculture Drug Response Assay (HDRA) effectively differentiates drug sensitivity in various soft tissue sarcoma (STS) subtypes.
• Trabectedin (THP) and Doxorubicin (ADM) show promising efficacy for STS treatment, with specific sensitivities noted for different histological types.
• Individualized treatment strategies based on HDRA testing are necessary to improve therapeutic outcomes for the diverse spectrum of STS.